Table 3.

Clinical and laboratory data and percentage of abnormal findings in patients with pandemic FLUA H1N1v infection^a

Clinical/laboratory observation	N	Value	% of patients with abnormal findings	P value
				Univariate analysis	Multivariate analysis
Temp ≥ 38 (°C)
Survivors	24/40		60	NS
Nonsurvivors	11/22		50
Pulse rate > 100/min
Survivors	18/36		50	NS
Nonsurvivors	11/22		50
Respiration > 30/min
Survivors	17/39		44	NS
Nonsurvivors	9/17		53
Systolic BP ≤ 90 mm Hg
Survivors	21/28		75	NS
Nonsurvivors	16/21		76
SpO2 ≤ 90%
Survivors	15/38		39	0.01	NS
Nonsurvivors	15/21		71
Creatine phosphokinase concn > 130 IU/ml
Survivors	4/35		11	0.01	0.003
Nonsurvivors	11/21		52
LDH concn > 225 IU/ml
Survivors	6/32		19	0.06	NS
Nonsurvivors	13/20		65
Comorbidities
Survivors	21/43		49	NS	NS
Nonsurvivors	13/24		54
Demographic data
Median (IQR) age (yr)
Survivors		26 (8–36)		0.0005	0.03
Nonsurvivors		42.5 (30–50)
Gender (no. male:no. female)
Survivors		18:25		NS
Nonsurvivors		10:14
Median (IQR) time interval between onset of disease and hospitalization (days)
Survivors		4 (2–7)		NS
Nonsurvivors		5 (4–6)
Median (IQR) time interval between onset of disease and antiviral use (days)
Survivors		4 (2–6)		0.03	NS
Nonsurvivors		5 (3.7–7.5)

^aN, number of patients with alterations/number with medical records with the information; BP, blood pressure; SpO₂, oxygen saturation; IQR, interquartile range; NS, not significant. Boldface data indicate a statistically significant difference.